Business - Briefly   

USFDA nod for Ranbaxy's Gabapentin

CHENNAI: Ranbaxy Laboratories has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Gabapentin capsules. The drug is for the management of postherpetic neuralgia in adults, says a Bombay Stock Exchange release.

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Tamil Nadu | Andhra Pradesh | Karnataka | Kerala | New Delhi | Other States | International | Opinion | Business | Sport | Miscellaneous | Entertainment |
Advts: Classifieds | Employment | Obituary | Updates: Breaking News |

Stories in this Section

• New omnibus trade policy on August 31
• Price stability is the main objective, says Y. V. Reddy
• Marginal dip in inflation
• Bose dares auto world with smart suspension
• BSNL announces lower cellular rates
• Infosys looking for second location in China?
• Rupee consolidates
• Market snaps three-day winning streak
• Financial switch dedicated to the nation
• Tata Steel targets 5 million tonnes output
• Exempted from making open offer
• Blue Star's new initiatives
• Exchange rates
• Bullion rates
• New directors for two banks
• Oracle's offer for PeopleSoft
• Electrolux ups rank
• Reliance product gains acceptance
• Virinchi Technologies pays 5 p.c.
• USFDA nod for Ranbaxy's Gabapentin
• Nucleus bags Philippines order
• MIMS aims at deemed university status
• Menlo's vendor inventory services
• Cold storage at Palangarai
• Barista to scale up operations

Copyright © 2004, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu